PMID- 16469488
OWN - NLM
STAT- MEDLINE
DCOM- 20070612
LR  - 20220409
IS  - 0954-6111 (Print)
IS  - 0954-6111 (Linking)
VI  - 100
IP  - 9
DP  - 2006 Sep
TI  - Long-term moxifloxacin in complicated tuberculosis patients with adverse 
      reactions or resistance to first line drugs.
PG  - 1566-72
AB  - STUDY OBJECTIVES: To test safety and tolerability of long-term moxifloxacin in 
      resistant tuberculosis (TB) patients and patients with intolerance to first line 
      anti-TB drugs. DESIGN: Clinical evaluation of adverse events (AEs) during 
      prolonged moxifloxacin treatment. SETTING: TB Unit of the Regional TB Reference 
      Center, Villa Marelli Institute, Niguarda Ca'Granda Hospital, Milan, Italy 
      PATIENTS AND INTERVENTIONS: Patients treated with moxifloxacin, 400 mg orally 
      once daily for TB in the Villa Marelli Institute from January 2001 to December 
      2003 were enrolled. RESULTS: Thirty-eight patients were treated with moxifloxacin 
      at the Villa Marelli Institute in the study period, for multidrug resistant (MDR) 
      TB (14, 36.8%), for intolerance to first line anti-TB drugs (9, 23.7%), for 
      combined resistance and intolerance to first line anti-TB drugs (12, 31.6%), 
      other reasons (3, 7.9%). The mean duration of moxifloxacin treatment was 6.3 +/- 
      5.2 months. Twelve (31.6%) patients reported at least an AE due to moxifloxacin, 
      mostly gastrointestinal (8, 21.0%), general (5, 13.2%) and central nervous system 
      (3, 7.9%) AEs. In 4 (10.5%) patients the drug was withdrawn for major AEs; no 
      irreversible or fatal events were recorded. Most of the patients (31, 81.6%) 
      reported a treatment success, even if the success rate was lower in MDR TB 
      patients (8/14, 51.7%). CONCLUSIONS: Despite the fact that a large proportion of 
      patients experienced at least an AE due to moxifloxacin, the drug resulted safe 
      in the long-term administration for complicated TB cases.
FAU - Codecasa, Luigi Ruffo
AU  - Codecasa LR
AD  - TB Unit, Villa Marelli Inst., Niguarda Hospital, Regional Reference Centre for 
      TB, Viale Zara 81, 20159 Milan, Italy. luigiruffo.codecasa@fastwebnet.it
FAU - Ferrara, Giovanni
AU  - Ferrara G
FAU - Ferrarese, Maurizio
AU  - Ferrarese M
FAU - Morandi, Maria Antonietta
AU  - Morandi MA
FAU - Penati, Valeria
AU  - Penati V
FAU - Lacchini, Carla
AU  - Lacchini C
FAU - Vaccarino, Patrizia
AU  - Vaccarino P
FAU - Migliori, Giovanni Battista
AU  - Migliori GB
LA  - eng
PT  - Journal Article
DEP - 20060215
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Antitubercular Agents)
RN  - 0 (Aza Compounds)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Quinolines)
RN  - U188XYD42P (Moxifloxacin)
SB  - IM
MH  - Adult
MH  - Antitubercular Agents/adverse effects/*therapeutic use
MH  - Aza Compounds/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Resistance, Multiple, Bacterial/drug effects
MH  - Female
MH  - Fluoroquinolones
MH  - Humans
MH  - Italy
MH  - Male
MH  - Moxifloxacin
MH  - Quinolines/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Tuberculosis, Multidrug-Resistant/*drug therapy
EDAT- 2006/02/14 09:00
MHDA- 2007/06/15 09:00
CRDT- 2006/02/14 09:00
PHST- 2005/09/24 00:00 [received]
PHST- 2005/12/11 00:00 [revised]
PHST- 2006/01/02 00:00 [accepted]
PHST- 2006/02/14 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2006/02/14 09:00 [entrez]
AID - S0954-6111(06)00007-2 [pii]
AID - 10.1016/j.rmed.2006.01.002 [doi]
PST - ppublish
SO  - Respir Med. 2006 Sep;100(9):1566-72. doi: 10.1016/j.rmed.2006.01.002. Epub 2006 
      Feb 15.